Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent

Pre-clinical studies of EC2629, a highly potent folate- receptor-targeted DNA crosslinking agent

Abstract Folate receptor (FR)-targeted small molecule drug conjugates (SMDCs) have shown promising results in early stage clinical trials with microtubule destabilizing agents, such as vintafolide and EC1456. In our effort to develop FR-targeted SMDCs with varying mechanisms of action, we synthesize...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Joseph A. Reddy, Melissa Nelson, Christina Dircksen, Marilynn Vetzel, Theresa Johnson, Vicky Cross, Elaine Westrick, LongWu Qi, Spencer Hahn, Hari Krishna Santhapuram, Garth Parham, Kevin Wang, Jeremy F. Vaughn, Albert Felten, Michael Pugh, June Lu, Patrick Klein, Iontcho R. Vlahov, Christopher P. Leamon
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2020
Materias:
Medicine
R
Science
Q
Acceso en línea:https://doaj.org/article/62cffd133d60412fb62fcc23f334889b
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares